2. MAPK/ERK Pathway Cell Cycle/DNA Damage PI3K/Akt/mTOR Stem Cell/Wnt NF-κB Metabolic Enzyme/Protease Immunology/Inflammation Autophagy Apoptosis Anti-infection
  3. JNK IRE1 Akt mTOR YAP Reactive Oxygen Species (ROS) Autophagy Apoptosis Ferroptosis Fungal
  4. 6-Methoxydihydrosanguinarine

6-Methoxydihydrosanguinarine is an alkaloid with activity across multiple cancer cell types. 6-Methoxydihydrosanguinarine activates IRE1/JNK signaling, blocks Akt/mTOR and PI3K/AKT/mTOR pathways, reduces expression of Cdc25C, CyclinB1, Cdc2, YAP/TAZ, Survivin, GPX4, and EGFR, upregulates IRE1 and DR5, and activates JNK and caspases. 6-Methoxydihydrosanguinarine induces apoptosis, G2/M phase arrest, DNA damage, ROS generation, lipid peroxidation, ferroptosis, autophagy, and suppresses cancer cell growth. 6-Methoxydihydrosanguinarine disruptes the biofilm formation of Candida albicans (C. albicans). 6-Methoxydihydrosanguinarine can be used for the research of non-small cell lung cancer, hepatocellular carcinoma, melanoma, colon carcinoma, ovarian cancer and breast cancer.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

6-Methoxydihydrosanguinarine

6-Methoxydihydrosanguinarine 構造式

CAS 番号 : 72401-54-8

容量 価格（税別） 在庫状況 数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 330 在庫あり
Solution
10 mM * 1 mL in DMSO USD 330 在庫あり
Solid
1 mg $140 在庫あり
5 mg $300 在庫あり
10 mg $450 在庫あり
50 mg   お問い合わせ  
100 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 0 publication(s) in Google Scholar

Other Forms of 6-Methoxydihydrosanguinarine:

6-Methoxydihydrosanguinarine 関連抗体

Top Publications Citing Use of Products

JNK アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
JNK1 JNK2 JNK3 JNK

Akt アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
Akt Akt1 Akt2 Akt3

mTOR アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
mTOR mTORC1 mTORC2

YAP アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
YAP/TAZ YAP/TAZ-TEAD TEAD YAP1

  • 生物活性

  • 純度とドキュメンテーション

  • 参考文献

  • カスタマーレビュー

製品説明

6-Methoxydihydrosanguinarine is an alkaloid with activity across multiple cancer cell types. 6-Methoxydihydrosanguinarine activates IRE1/JNK signaling, blocks Akt/mTOR and PI3K/AKT/mTOR pathways, reduces expression of Cdc25C, CyclinB1, Cdc2, YAP/TAZ, Survivin, GPX4, and EGFR, upregulates IRE1 and DR5, and activates JNK and caspases. 6-Methoxydihydrosanguinarine induces apoptosis, G2/M phase arrest, DNA damage, ROS generation, lipid peroxidation, ferroptosis, autophagy, and suppresses cancer cell growth. 6-Methoxydihydrosanguinarine disruptes the biofilm formation of Candida albicans (C. albicans). 6-Methoxydihydrosanguinarine can be used for the research of non-small cell lung cancer, hepatocellular carcinoma, melanoma, colon carcinoma, ovarian cancer and breast cancer[1][2][3][4][5][6][7].

IC50 & Target

IC50: 0.61 μM (MCF-7 cells)
IC50: 0.54 μM (SF-268 cells)[1]
Cellular Effect
Cell Line Type Value Description References
A549 IC50
1.59 μM
Compound: 8j
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
[PMID: 33479636]
NCI-H1975 IC50
1.17 μM
Compound: 8j
Antiproliferative activity against human H1975 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human H1975 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
[PMID: 33479636]
体外実験

6-Methoxydihydrosanguinarine (0.15625-10 μM; 24 h) suppresses the viability of A549 and H1299 NSCLC cells in a dose-dependent manner, with IC50 values of 2.154 μM and 2.586 μM respectively after 24 h treatment[1].
6-Methoxydihydrosanguinarine (0.5-2 μM; 24 h) induces G2/M phase arrest in A549 and H1299 NSCLC cells after 24 h treatment at 2 μM, and G1 phase arrest in H1299 cells at lower concentrations[1].
6-Methoxydihydrosanguinarine (0.5-2 μM; 24 h) downregulates cell cycle-related proteins Cdc25C, p-Cdc25C, cyclinB1, and Cdc2 in A549 and H1299 NSCLC cells after 24 h treatment[1].
6-Methoxydihydrosanguinarine (0.5-2 μM; 24 h) dose-dependently activates the caspase cascade and induces PARP cleavage in A549 and H1299 NSCLC cells after 24 h treatment, promoting apoptotic cell death[1].
6-Methoxydihydrosanguinarine (0.5-2 μM; 24 h) dose-dependently inhibits the Akt/mTOR signaling pathway in A549 and H1299 NSCLC cells after 24 h treatment by reducing Akt and p70S6K phosphorylation and total protein levels[1].
6-Methoxydihydrosanguinarine (0.5-2 μM; 24 h) dose-dependently blocks the YAP/TAZ oncogenic signaling axis in A549 and H1299 NSCLC cells after 24 h treatment by reducing YAP, TAZ, and survivin expression and increasing LATS1/2 phosphorylation[1].
6-Methoxydihydrosanguinarine (0.5-2 μM; 24 h) dose-dependently induces apoptosis in A549 and H1299 NSCLC cells after 24 h treatment[1].
6-Methoxydihydrosanguinarine (0.5-2 μM; 12 h) dose-dependently elevates intracellular ROS levels in A549 and H1299 NSCLC cells after 12 h treatment[1].
6-Methoxydihydrosanguinarine (0.5-2 μM; 24 h) dose-dependently activates the IRE1/JNK signaling pathway in A549 and H1299 NSCLC cells after 24 h treatment[1].
6-Methoxydihydrosanguinarine (0.125-8 μM; 24 h) dose-dependently reduces cell viability in HepG2 and Huh7 cells, with IC50 values of 2.83 μM and 3.46 μM after 24 h of treatment[2].
6-Methoxydihydrosanguinarine hydrochloride (6-MS) (1-2 μM; 12 h) dose-dependently increases intracellular ROS production in HepG2 and Huh7 cells after 12 h of treatment[2].
6-Methoxydihydrosanguinarine (0.5-2 μM; 24 h) dose-dependently inhibits the EGFR/Akt signaling pathway, as measured by reduced EGFR expression and Akt phosphorylation, in HepG2 and Huh7 cells after 24 h of treatment[2].
6-Methoxydihydrosanguinarine (0.5-2 μM; 24 h) activates the JNK and p38MAPK pathways in HepG2 and Huh7 cells after 24 h of treatment, with JNK activation being required for 6-MS-induced PARP cleavage (a marker of apoptosis)[2].
6-Methoxydihydrosanguinarine (0.5-2 μM; 24 h) dose-dependently upregulates DR4 and DR5 expression in HepG2 and Huh7 cells after 24 h of treatment, and DR5 upregulation is required for 6-Methoxydihydrosanguinarine hydrochloride-mediated sensitization to TRAIL-induced apoptosis[2].
6-Methoxydihydrosanguinarine (0-1.5 μM; 12 h) potently inhibits the viability of HLE and HCCLM3 hepatocellular carcinoma cells with IC50 values of 1.129 μM and 1.308 μM respectively after 12 h, and is less cytotoxic to normal LX-2 hepatic stellate cells[3].
6-Methoxydihydrosanguinarine (1 μM (HLE), 1.5 μM (HCCLM3); 12 h) induces cell death in hepatocellular carcinoma cells after 12 h of treatment, and this effect is mediated via ferroptosis, as shown by reversal with ferroptosis inhibitors[3].
6-Methoxydihydrosanguinarine (1 μM (HLE), 1.5 μM (HCCLM3); 6 h) downregulates GPX4 expression at the transcriptional level in hepatocellular carcinoma cells after 6 h of treatment[3].
6-Methoxydihydrosanguinarine (1-50 μM; 24 h) selectively inhibits human A375 melanoma cell viability over normal NHDF cells, with an IC50 of 2.85 μM after 24 h[4].
6-Methoxydihydrosanguinarine (0-32 μM; 24 h) potently reduces MCF-7 breast cancer cell viability in a time- and dose-dependent manner, with an IC50 of 4.21 μM after 24 h[5].
6-Methoxydihydrosanguinarine (2-4 μM; 6-24 h) induces apoptosis in MCF-7 breast cancer cells by upregulating pro-apoptotic proteins and downregulating anti-apoptotic proteins, induces autophagy by upregulating autophagy-related proteins, and inhibits the PI3K/AKT/mTOR pathway by reducing phosphorylation of key pathway proteins[5].
6-Methoxydihydrosanguinarine downregulates the expression of EFG1, CDC35, RAS1, and TPK2, all of which are critical components of the cAMP pathway. Furthermore, 6-Methoxydihydrosanguinarine changes the membrane permeability of C. albicans and caused reactive oxygen species accumulation, leading to cell death[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

6-Methoxydihydrosanguinarine 関連抗体

Cell Viability Assay[1]

Cell Line: A549, H1299 non-small cell lung cancer (NSCLC) cells
Concentration: 0.15625 μM, 0.3125 μM, 0.625 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM
Incubation Time: 24 h
Result: Caused a dose-dependent reduction in cell viability in both cell lines, with IC50 values of 2.154 μM for A549 cells and 2.586 μM for H1299 cells.

Cell Cycle Analysis[1]

Cell Line: A549, H1299 non-small cell lung cancer (NSCLC) cells
Concentration: 0.5 μM, 1 μM, 2 μM
Incubation Time: 24 h
Result: Induced G2/M phase arrest in both A549 and H1299 cells at 2 μM, with a concomitant reduction in G1 or S phase cells.
Induced G1 phase block in H1299 cells at lower concentrations.

Western Blot Analysis[1]

Cell Line: A549, H1299 non-small cell lung cancer (NSCLC) cells
Concentration: 0.5 μM, 1 μM, 2 μM
Incubation Time: 24 h
Result: Significantly decreased the protein levels of Cdc25C, p-Cdc25C, cyclinB1, and Cdc2 in both cell lines.
Significantly increased the protein levels of γ-H2AX in both A549 and H1299 cells, indicating induction of DNA double-strand breaks.
Caused a dose-dependent increase in the cleavage of caspase-3, caspase-8, caspase-9, and PARP in both A549 and H1299 cells.\nCaused a dose-dependent decrease in protein expression of p-Akt, total Akt, p-p70S6K, and total p70S6K in both A549 and H1299 cells, indicating inhibition of the Akt/mTOR pathway.
Caused a dose-dependent decrease in protein expression of YAP, TAZ, and survivin, and an increase in p-LATS1/2 protein expression in both A549 and H1299 cells, indicating inhibition of the YAP/TAZ oncogenic axis.

Western Blot Analysis[5]

Cell Line: Human breast cancer MCF-7 cells
Concentration: 2 μM, 4 μM
Incubation Time: 6, 12, 24 h
Result: Increased cleaved caspase-7/caspase-7, cleaved PARP/PARP, and BAX expression, and decreased Bcl-2 expression, in dose- and time-dependent manners.
Increased LC3 II/LC3 I and Atg5 expression in dose- and time-dependent manners.
Decreased P-PI3K/PI3K, P-AKT/AKT, and P-mTOR/mTOR ratios in a dose-dependent manner.
体内実験

6-Methoxydihydrosanguinarine (5 mg/kg; i.p.; daily; 14 days) decreases tumor volume and weight in a Caov-3 ovarian cancer mouse xenograft model[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female BALB/c-nude mice (5-week-old) were injected subcutaneously ventrally CAOV3 cells (5×106)[7]
Dosage: 5 mg/kg
Administration: i.p.; daily; 14 days
Result: The tumor volume and weight were much lower
Showed no physiologically harmful effects on mice.
分子量

363.36

分子式

C21H17NO5
CAS 番号
Appearance

Solid

Color

Off-white to pink

SMILES

CN1C2=C3C(C=C4OCOC4=C3)=CC=C2C5=C(C6=C(OCO6)C=C5)C1OC
Structure Classification
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
溶剤 & 溶解度
体外: 

DMSO : 12.5 mg/mL (34.40 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.7521 mL 13.7605 mL 27.5209 mL
5 mM 0.5504 mL 2.7521 mL 5.5042 mL
10 mM 0.2752 mL 1.3760 mL 2.7521 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始）

C1

×
体積 （開始）

V1

=
濃度 （終了）

C2

×
体積 （終了）

V2

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 3.85 mg/mL (10.60 mM); Clear solution

    This protocol yields a clear solution of ≥ 3.85 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (38.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション

純度: 99.88%

COA (253 KB)

取扱説明書 (2659 KB)
参考文献

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.7521 mL 13.7605 mL 27.5209 mL 68.8023 mL
5 mM 0.5504 mL 2.7521 mL 5.5042 mL 13.7605 mL
10 mM 0.2752 mL 1.3760 mL 2.7521 mL 6.8802 mL
15 mM 0.1835 mL 0.9174 mL 1.8347 mL 4.5868 mL
20 mM 0.1376 mL 0.6880 mL 1.3760 mL 3.4401 mL
25 mM 0.1101 mL 0.5504 mL 1.1008 mL 2.7521 mL
30 mM 0.0917 mL 0.4587 mL 0.9174 mL 2.2934 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

6-Methoxydihydrosanguinarine Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量   濃度   体積   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

6-Methoxydihydrosanguinarine72401-54-8JNKIRE1AktmTORYAPReactive Oxygen Species (ROS)AutophagyApoptosisFerroptosisFungalc-Jun N-terminal kinaseInositol requiring enzyme 1PKBProtein kinase BMammalian target of RapamycinYes-associated proteinMCF-7SF-268lkaloidcancerInhibitorinhibitorinhibit

最近チェックした製品:

オンラインお問い合わせ

Your information is safe with us. * Required Fields.

製品名

  

カスタマ需要量 *

お名前 *

 

タイトル

メールアドレス *

 

電話番号 *

デパートメント

 

組纖名 *

市区町村

都道府県

国或いは地域 *

      

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
6-Methoxydihydrosanguinarine
製品番号:
HY-N3000
数量:
MCE 日本正規代理店:

カスタマーレビュー

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

製品名

  

Lot #

お名前 *

 

メールアドレス *

電話番号 *

 

部門 *

組纖名 *

 

国或いは地域 *

備考

Request for HNMR Report

We have received your request and will respond to you as soon as possible.